MIRA Pharmaceuticals Inc. (MIRA)
0.89
0.03 (2.90%)
At close: Apr 14, 2025, 3:59 PM
0.90
1.68%
After-hours: Apr 14, 2025, 04:59 PM EDT
2.90% (1D)
| Bid | 0.84 |
| Market Cap | 14.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.85M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -1.74 |
| Forward PE | -2.06 |
| Analyst | Buy |
| Ask | 0.91 |
| Volume | 87,955 |
| Avg. Volume (20D) | 257,998 |
| Open | 0.87 |
| Previous Close | 0.86 |
| Day's Range | 0.87 - 0.90 |
| 52-Week Range | 0.51 - 5.01 |
| Beta | 2.07 |
About MIRA
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Aug 14, 2023
Employees 2
Stock Exchange NASDAQ
Ticker Symbol MIRA
Website https://mirapharmaceuticals.com
Analyst Forecast
According to 2 analyst ratings, the average rating for MIRA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 1481.92% from the latest price.
Stock Forecasts5 months ago
+21.71%
MIRA Pharmaceutical shares are trading higher afte...
Unlock content with
Pro Subscription
6 months ago
+8.41%
MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data for Ketamir-2,
